
The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.
Click the title above for a link to open the Pharmaceutical Executive October 2023 issue in an interactive PDF format.
about 3 years ago
A Blueprint for Balanceabout 3 years ago
Biopharma Stock Check: Market Review and Outlookabout 3 years ago
Securing the Safety Net in Drug Access and Supportabout 3 years ago
Obesity Drugs in the Payer Market: What to Expectabout 3 years ago
Boosting Clinical Trials and Patient Access with Payer Insightsabout 3 years ago
Are We Close to a Peak in Interest Rates?about 3 years ago
The Harms of ‘Helicopter Research’ in the Life Sciencesabout 3 years ago
The Rising Importance of Patient Advocacy Innovations in Asiaabout 3 years ago
A Fond Farewell





